Cétose ou acidocétose diabétique euglycémique chez des patients diabétiques de type 2 traités par inhibiteurs du SGLT2 : une série de cas cliniques en Belgique
Authors:
- 1 April 2020
- journal article
- research article
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 41 (4) , 226-231
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- SGLT2 Inhibitors May Predispose to KetoacidosisThe Journal of Clinical Endocrinology & Metabolism, 2015
- SGLT inhibition and euglycaemic diabetic ketoacidosisThe Lancet Diabetes & Endocrinology, 2015
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 InhibitionDiabetes Care, 2015
- Glucagon Regulates Hepatic Kisspeptin to Impair Insulin SecretionCell Metabolism, 2014
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJournal of Clinical Investigation, 2014
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJournal of Clinical Investigation, 2014
- Ketoacidosis occurs in both Type 1 and Type 2 diabetes— a population‐based study from Northern SwedenDiabetic Medicine, 2008
- Hyperosmolar Coma: Cellular Dehydration and the Serum Sodium ConcentrationAnnals of Internal Medicine, 1989
- KETOTIC HYPEROSMOLAR COMAThe Lancet, 1973
- Euglycaemic Diabetic KetoacidosisBMJ, 1973